Question explored with the scientific record
Is the Harv vaccine safe
There is no vaccine called "Harv." No retrieved study mentions it. The question cannot be answered because the product does not appear to exist.
The evidence you provided covers a range of real vaccines: Recombivax HB, Comvax, Menactra, tetanus/diphtheria toxoids, Prevnar 13, PedvaxHIB, RabAvert, JE-Vax, DTaP, HPV, influenza, MMR, polio (IPV), rotavirus, BCG, Tdap, and several COVID-19 vaccines [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]. None of these is named "Harv." The records also include studies on tick activity, livestock fertility, and bacterial growth under simulated microgravity [11, 12, 13]. None of that is relevant to a vaccine called Harv.
If you meant a different vaccine, please name it exactly. If you are asking about a product not yet approved or not widely known, the absence of any safety data in this retrieval means there is no evidence to evaluate. The burden of proof is on whoever is asking you to accept the injection, and that burden has not been met here.
My call: there is no evidence to assess because the named vaccine does not appear in any retrieved record. Confidence: not clear.
Sources used 13
-
The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines
The study presents the Ontology of Vaccine Adverse Events (OVAE), a framework developed to systematically represent and analyze adverse events associated with US-licensed human vaccines, facilitating better understanding and classification of vaccine-specific adverse events (VAE…
DOI: 10.1186/2041-1480-4-40 -
Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12
This study analyzes adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) following the administration of the inactivated poliovirus vaccine (IPV) from 2000 to 2012, finding a low incidence of serious adverse events and no new safety concerns associate…
DOI: 10.1016/s1473-3099(15)00059-6 -
Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997–2005
This study reviews adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) following the administration of the Purified Chick Embryo Cell (PCEC) rabies vaccine in the U.S. from 1997 to 2005, finding that most reported adverse events were non-serious and con…
DOI: 10.1016/j.vaccine.2007.02.075 -
Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013–June 2014
This study analyzes reports from the Vaccine Adverse Event Reporting System (VAERS) regarding the safety of the quadrivalent live attenuated influenza vaccine (LAIV4) during its first season of use, finding no concerning patterns and highlighting the need for education on proper…
DOI: 10.1016/j.vaccine.2015.01.080 -
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015
This study analyzes the safety of the quadrivalent human papillomavirus vaccine (4vHPV) using data from the Vaccine Adverse Event Reporting System (VAERS) from 2009 to 2015, finding no new or unexpected safety concerns.
DOI: 10.1016/j.vaccine.2018.02.034 -
Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis
This study systematically compares the adverse event profiles associated with Bacillus Calmette-Guerin (BCG) as a preventive tuberculosis vaccine and as a therapeutic bladder cancer vaccine, utilizing data from the Vaccine Adverse Event Reporting System (VAERS) and literature me…
DOI: 10.1371/journal.pone.0164792 -
Adverse events after Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005–2010
This study reviews adverse event reports following the off-label administration of the Tdap vaccine to adults aged 65 years and older, utilizing data from the Vaccine Adverse Event Reporting System (VAERS) from 2005 to 2010, and finds no significant safety concerns warranting fu…
DOI: 10.1016/j.vaccine.2011.05.100 -
Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia
This study investigates the incidence of adverse events following primary and booster doses of mRNA, viral vector, and inactivated Covid-19 vaccines among medical professionals in Malaysia, revealing significant differences in adverse event profiles across vaccine types.
DOI: 10.1186/s12879-025-11254-1 -
SAFETY MONITORING OF COVID-19 VACCINE: IN A TERTIARY CARE HOSPITAL IN HARYANA
First-dose ChAdOx1 nCoV-19 vaccination in 1907 recipients resulted in mostly mild, self-limiting adverse events (reported by 70) that resolved within two days, indicating acceptable short-term safety.
DOI: 10.22159/ijpps.2023v15i3.47287 -
The Facts About Vaccine Safety
This article analyzes US Vaccine Injury Compensation Program (VICP) data to quantify the risk of serious vaccine-related adverse events per million doses and to illustrate the vaccine risk-benefit balance.
DOI: 10.1093/cid/ciaa697 -
18 OVARIAN SUPPRESSION WITH THE PROGESTIN LEVONORGESTREL IMPROVES OVULATION INDUCTION FOR ARTIFICIAL INSEMINATION IN THE DOMESTIC CAT
Multiple livestock fertility studies evaluate semen profiling, AI protocols, and hormonal treatments across cattle, buffalo, cats, and turkeys, including cell profiling under simulated microgravity, to understand drivers of pregnancy success and reproductive efficiency.
DOI: 10.1071/rdv16n1ab18 -
Refining mechanistic models to better predict larval and nymphal activity patterns of Ixodes scapularis
Adding humidity-dependent questing and low overwinter larval-to-nymphal development to a mechanistic Ixodes scapularis model improves predicted larval and nymphal seasonal activity at three NEON sites, with humidity as the dominant driver and larvae most sensitive.
DOI: 10.64898/2026.08.26.747079 -
Rotating wall vessel exposure alters protein secretion and global gene expression in Staphylococcus aureus
This study uses a rotating wall vessel to simulate microgravity and low-shear conditions to show that Staphylococcus aureus grown under continuous rotation secretes fewer extracellular proteins, exhibits limited but specific changes in global gene expression, and that deletion o…
DOI: 10.1017/s1473550411000346